Printer Friendly

Articles from M2 Pharma (September 11, 2017)

1-35 out of 35 article(s)
Title Author Type Words
Amgen, Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980. 799
Armo BioSciences Presents Additional Data from AM0010 Trials at ESMO 2017 Congress. 425
AstraZeneca's Duaklir meets primary endpoints in Phase III Amplify trial. 161
Chesapeake Urology signs urology services partnership agreement with Urological Associates, PA. 231
Eli Lilly plans workforce reduction. 181
First Human Patient Treated with AmpliPhi Biosciences' AB-SA01 Targeting Staphylococcus Aureus. 417
Gecko Biomedical granted CE Mark approval for its SETALUM Sealant. 190
Genesis CancerCare Queensland uses the Venezia Brachytherapy Applicator in patients with advanced cervical cancer for the first time. 183
Glenmark Pharmaceuticals granted final FDA approval to market generic version of Rythmol SR. 142
GSK exercises option to receive exclusive license for SPEAR T-cell receptor therapy from Adaptimmune. 187
Independent DMC Okays Continuation of United Therapeutics Study of Orenitram. Clinical report 360
Infant Bacterial Therapeutics shares topline data of Phase II study of IBP-9414. Clinical report 203
Innate Pharma presents new preclinical data for its first-in-class clinical stage antibodies IPH5401 and monalizumab. 214
Kura Oncology reports positive top-line results from a phase two trial for tipifarnib. 198
Medivir announces discontinuation by Janssen R&D of JNJ-4178 development. 164
Merck Presents Data on Keytruda (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2017 Congress. 405
Merck Presents Five Months of Additional Data from KEYNOTE-021 Study of Keytruda (pembrolizumab) in Combination with Pemetrexed and Carboplatin (pem/carbo) in Patients with Nonsquamous. 439
Miralles Named Chief Executive Officer at Vividion Therapeutics. 434
NIAID, Zavante Partner in Clinical Trial of Zolyd as Bacterial Pneumonia Treatment. 400
Ocular Therapeutix Names Goldstein as Chief Medical Officer. 254
Ozmosi Launches a Global Clinical Trials Database. 190
Pfizer Presents Overall Survival Data of Xalkori in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. 320
Pharming Group NV concludes End-of-Phase 2 interactions with the US FDA for the expanded use of RUCONEST in HAE patients. 306
PharmScript reports acquisition of MedCart Pharmacy for undisclosed value. 133
Puma biotechnology Data from Trial of Neratinib in HER2-Positive Breast Cancer Demonstrates Continued Benefit After 5 years. 439
Regeneron and Sanofi partnership awarded US FDA breakthrough therapy designation for cemiplimab for squamous cell carcinoma. 252
Replimune announces USD55m from its Series B financing with investors. 183
Replimune Closes USD 55m Financing. 306
Replimune names Howard L. Kaufman, MD, FACS as CMO. 186
Researchers trialling treatment combinations stop spread of melanoma. 635
Sanofi and Regeneron's Phase 3 dupilumab sees positive top-line results. 215
Spirosure Launches Fenom PRO at European Respiratory Society International Congress 2017. 211
Teva hires Kare Schultz as CEO. 218
Zavante Therapeutics partners with NIAID to assess ZOLYD for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. 331
Zavante Therapeutics signs clinical trial contract with National Institute of Allergy and Infectious Disease. 134

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters